Gabriele Imbalzano

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10198430/publications.pdf

Version: 2024-02-01

20 papers

310 citations

8 h-index 940533 16 g-index

20 all docs 20 docs citations

times ranked

20

431 citing authors

#	Article	IF	Citations
1	Differential response to pallidal deep brain stimulation among monogenic dystonias: systematic review and meta-analysis. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 426-433.	1.9	49
2	Neurological comorbidity and severity of COVID-19. Journal of Neurology, 2021, 268, 762-769.	3.6	47
3	COVID-19 in Parkinson's disease: Report on prevalence and outcome. Parkinsonism and Related Disorders, 2020, 80, 7-9.	2.2	42
4	Anxiety, depression, and worries in advanced Parkinson disease during COVID-19 pandemic. Neurological Sciences, 2021, , 1.	1.9	29
5	Safety and efficacy of tolcapone in Parkinson's disease: systematic review. European Journal of Clinical Pharmacology, 2021, 77, 817-829.	1.9	24
6	Gene Therapy in Movement Disorders: A Systematic Review of Ongoing and Completed Clinical Trials. Frontiers in Neurology, 2021, 12, 648532.	2.4	21
7	Implementation of Mobile Health Technologies in Clinical Trials of Movement Disorders: Underutilized Potential. Neurotherapeutics, 2020, 17, 1736-1746.	4.4	20
8	Beyond 10 years of levodopa intestinal infusion experience: Analysis of mortality and its predictors. Parkinsonism and Related Disorders, 2020, 76, 98-103.	2.2	11
9	Time to onset and duration of botulinum toxin efficacy in movement disorders. Journal of Neurology, 2022, 269, 3706-3712.	3.6	11
10	Speech Impairment in Parkinson's Disease: Acoustic Analysis of Unvoiced Consonants in Italian Native Speakers. IEEE Access, 2021, 9, 166370-166381.	4.2	10
11	Neurological comorbidities and COVID-19-related case fatality: A cohort study. Journal of the Neurological Sciences, 2021, 428, 117610.	0.6	8
12	SARS-CoV-2 vaccination, Parkinson's disease, and other movement disorders: case series and short literature review. Neurological Sciences, 2022, 43, 5165-5168.	1.9	8
13	Levodopa/Carbidopa Intestinal Gel Longâ€√erm Outcome in Parkinson's Disease: Focus on Dyskinesia. Movement Disorders Clinical Practice, 2020, 7, 930-939.	1.5	7
14	Early reversible leukoencephalopathy and unilateral sixth cranial nerve palsy in mild COVID-19 infection. Neurological Sciences, 2021, 42, 4899-4902.	1.9	7
15	Video analysis of long-term effects of levodopa-carbidopa intestinal gel on gait and posture in advanced Parkinson's disease. Neurological Sciences, 2020, 41, 1927-1930.	1.9	6
16	Low frequency subthalamic stimulation and event-related potentials in Parkinson disease. Parkinsonism and Related Disorders, 2021, 82, 123-127.	2.2	4
17	Deep brain stimulation outcomes in the malignant end of Parkinson's disease spectrum. Parkinsonism and Related Disorders, 2021, 86, 5-9.	2.2	2
18	Association between sleep disorders and cognitive dysfunctions in non-demented patients with advanced Parkinson's disease. Journal of Neurology, 2022, 269, 1538-1545.	3.6	2

#	Article	IF	CITATIONS
19	Tuning deep brain stimulation related depression by frequency modulation: A case report. Brain Stimulation, 2020, 13, 1265-1267.	1.6	1
20	Efficacy of safinamide as add-on therapy after subthalamic nucleus deep brain stimulation in Parkinson disease. Neurological Sciences, 2022, 43, 3187-3193.	1.9	1